Clinical trial
Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
NCT03041116 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
- Lead sponsor
- Travere Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 17, 2017
- Completion date
- December 30, 2019
- Enrollment
- 84 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.